Sara Coca Membribes, GU Clinical Research Fellow at Barts Health NHS Trust, shared Nature Reviews Drug Discovery’s post on X, adding:
“One to watch in solid tumors: MDX2001 is a first-in-human tetraspecific T-cell engager targeting cMET × TROP2 × CD3 × CD28.
The ongoing phase I/II trial is enrolling patients with >10 solid tumor types (including renal and prostate).”
Quoting Nature Reviews Drug Discovery‘s post:
“Multispecific T-cell engagers that bind three or more targets on cancer and immune cells promise to address the shortcomings of their bispecific predecessors – find out more in this news story in our August issue.”
Title: Multispecific T-cell engagers attract cancer drug developers
Authors: Asher Mullard.
Other articles about Sara Coca Membribes on OncoDaily.